Literature DB >> 27433957

Cardiac Structure and Function in Elite Para-cyclists with Spinal Cord Injury.

Jonathan H Kim1, Jennifer L Trilk, Ryan Smith, Irfan Asif, Paul Tim Maddux, Yi-An Ko, Michael S Emery.   

Abstract

PURPOSE: We sought to explore the association between the spinal cord injury (SCI) level on the cardiac structure and the function observed in elite para-cyclists.
METHODS: Cross-sectional echocardiographic data from 44 elite SCI hand cyclists (39.8 ± 9 yr, 68% male/32% female) stratified by the level of SCI (cervical, N = 9; T1-T5, N = 10; below T5, N = 25) and 19 non-SCI blind/visually impaired (BVI) tandem cyclists (32.4 ± 7 yr, 58% male/42% female) were analyzed before the initiation of international competition.
RESULTS: Compared with non-SCI BVI cyclists, cervical SCI para-cyclists were observed with lower indexed left ventricular (LV) mass (99.6 ± 12 vs 125 ± 20 g·m, P = 0.01), posterior wall thickness (4.5 ± 0.3 vs 5.8 ± 0.7 mm·m, P < 0.001), interventricular septal wall thickness (4.8 ± 0.5 vs 5.7 ± 0.7 mm·m; P = 0.03), and left atrial volume (21 ± 3.5 vs 28 ± 7 mL·m; P = 0.02). In multivariable analyses, cervical SCI was independently associated with decreased LV wall thickness [interventricular septum (β = -0.67, P = 0.01), posterior wall (β = -0.98, P = 0.001)], decreased LV mass (β = -21, P < 0.001), and decreased left atrial volume index (β = -6.9, P = 0.001) compared with other levels of SCI and non-SCI BVI cyclists. There were no differences in ventricular function among any of the athlete groups.
CONCLUSION: Compared with para-cyclists with lower levels of SCI, the athletes with cervical SCI demonstrate attenuated cardiac size and concentric LV hypertrophy.

Entities:  

Mesh:

Year:  2016        PMID: 27433957     DOI: 10.1249/MSS.0000000000000921

Source DB:  PubMed          Journal:  Med Sci Sports Exerc        ISSN: 0195-9131            Impact factor:   5.411


  1 in total

1.  C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling.

Authors:  Pan-Xia Wang; Zhuo-Ming Li; Si-Dong Cai; Jing-Yan Li; Ping He; Yi Huang; Guo-Shuai Feng; Hai-Bin Luo; Shao-Rui Chen; Pei-Qing Liu
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.